Thieme integrates Certara Chemaxon’s new generation chemical sketcher, Marvin, into its chemical databases Science of Synthesis and Pharmaceutical Substances

Latest version of Marvin is more accurate and user-friendly for Chemical Database Subscribers

Stuttgart, Germany & Radnor, PA, 2026 年 4 月 14 日 – Thieme Group and Certara, a global leader in model informed drug development Inc (Nasdaq: CERT) today announced the integration of Marvin with chemical databases, Science of Synthesis and Pharmaceutical Substances. Integrating the latest version of Marvin from Certara’s Chemaxon portfolio makes drawing chemical structures and reactions to find matches in the databases faster, more accurate and user-friendly.

Chemaxon, now part of the discovery software and services portfolio of Certara, develops cutting-edge scientific informatics software products used by the life sciences industry for research and development. Marvin, the portfolio’s web-based chemical drawing software, can easily be integrated into chemical databases and other chemistry software.

“Using multiple applications to draw compounds and calculate chemical properties is cumbersome and slows down scientific work. Marvin was developed as an all-in-one chemical sketcher to streamline these tasks, allowing chemists to spend less time drawing and more time driving scientific breakthroughs,” said Luca Szabó, Product Manager Marvin, Chemaxon

Thieme, a leading provider of information and services that contribute to the improvement of health and healthcare, is committed to delivering key information to life sciences professionals at the right time and in the right place. Discovering effective, practical experimental procedures that can be implemented quickly in the lab is central to chemists’ day-to-day work. With up-to-date information, chemists can begin designing and planning syntheses immediately.

A flexible, easy-to-use drawing tool with name-to-structure conversion is essential for chemical-reaction databases such as Science of Synthesis and Pharmaceutical Substances. Science of Synthesis provides full-text descriptions of organic transformations and synthetic methods as well as experimental procedures. It is a unique chemical information tool with insightful didactic reviews by experts that add real value to synthesis planning. Pharmaceutical Substances is an online tool that presents chemical structures and detailed synthetic routes, including starting materials and intermediates – for all significant APIs. All information is extracted from patent literature compiled by experienced experts in medicinal and pharmaceutical chemistry.

"We were pleased with the smooth migration: no development was required for the backend, and switching the frontend from the legacy Marvin JS to the new Marvin took only minimal developer time," said Dr. Alex Russell, Product Manager Chemistry Databases at Thieme Group. "The Chemaxon team is constantly working to simplify the integration process, enabling us to provide our users with improved tools while causing minimal disruption."

关于Certara

Chemaxon is a leading cheminformatics company that provides platforms, applications, and solutions to handle chemical entities in life sciences, biotechnology and other research industries. Certara 于 2024 年收购 Chemaxon，旨在填补研发周期（设计-合成-测试-分析）的空白，将有潜力的先导化合物引入生物模拟，加速新药上市。Certara 利用生物模拟软件、技术和服务加速药物研发，从而改变传统的药物研发方式。其客户包括超 2,600 家生物制药公司、学术机构和来自 70 个国家的监管机构。Learn more at certara.com

About Thieme

Thieme is a leading provider of information and services for the improvement of health and healthcare. With digital solutions in medicine and chemistry, Thieme supports information, communication and documentation processes in science, education, and patient care. Thieme’s services are designed to be of direct benefit to their target groups – medical students, physicians, nurses, scientists, hospitals, health insurance companies, and other healthcare professionals. They receive exactly the information and services they need in a specific work situation or career. Together with a broad network of experts and partners, the digital healthcare provider ensures that it sets the pace in medical science, didactics, and technology. The family-owned company employs more than 1,000 people worldwide and is committed to improving medicine and health every day with innovative new and further developments. For more information about Thieme, please visit https://www.thieme.com.